newsfilter
← Latest News
GlobeNewswire·

PRISM MarketView Highlights Four Small Caps Working on Alzheimer’s Disease for National Alzheimer’s Disease Awareness Month

  • PRISM MarketView published a National Alzheimer's Disease Awareness Month feature on four small-cap companies addressing treatment & testing.
  • The report follows the CTAD conference where Biogen reported a 38% decline reduction at two years for diranersen's lowest dose, Priavoid's PRI-002 missed efficacy endpoints, & Lilly ended mevidalen development.
  • Annovis Bio (NYSE: ANVS) expects Phase 3 DUET-AD trial topline results for buntanetap in March 2027 after a safety board recommended continuing the study.
  • AC Immune (NASDAQ: ACIU) reported antibody responses at all dose levels for its Takeda-partnered ACI-24 immunotherapy with no ARIA-E brain swelling across 74 patients.
  • IGC Pharma (NYSE American: IGC) completed dosing in its 170-patient CALMA trial for Alzheimer's agitation, with results expected in December 2026 or January 2027.
  • Firefly Neuroscience (NASDAQ: AIFF) has its FDA-cleared Evoke EEG System currently in use at over 85 U.S. clinical sites.
Company
PRISM MarketView
Keywords
PRISM MarketView, stocks, NASDAQ, Healthcare, Alzheimer's